Literature DB >> 24345846

A 4-polymorphism risk score predicts steatohepatitis in children with nonalcoholic fatty liver disease.

Valerio Nobili1, Benedetta Donati, Nadia Panera, Apirom Vongsakulyanon, Anna Alisi, Bruno Dallapiccola, Luca Valenti.   

Abstract

OBJECTIVE: Nonalcoholic fatty liver disease (NAFLD) has become the most common cause of chronic liver disease in industrialized countries in adults and children, following the trail of the epidemic diffusion of obesity. Nonalcoholic steatohepatitis (NASH) is a potentially serious form of NAFLD linked with a significant increase in overall and liver-related morbidity and mortality. Because diagnosis still requires liver biopsy, there is urgent need of developing noninvasive early markers. The aim of the present study was to assess whether the simultaneous detection of genetic risk factors could predict NASH.
METHOD: We enrolled 152 untreated, consecutive obese children and adolescents with biopsy-proven NAFLD and increased liver enzymes. The PNPLA3 rs738409 C>G (I148 M), SOD2 rs4880 C>T, KLF6 rs3750861 G>A, and LPIN1 rs13412852 C>T polymorphisms were detected by Taqman assays.
RESULTS: A multivariate logistic model based on the genetic risk factors significantly predicted NASH (area under the receiver-operating characteristic curve [AUC] 0.75, 95% confidence interval [CI] 0.67-0.82, P < 0.0001), performing better than a clinical risk score identified at stepwise regression based on age, aspartate aminotransferase levels, and diastolic blood pressure (AUC 0.66, 95% CI 0.57-0.75). A single cutoff value of the genetic risk score had 90% sensitivity and 36% specificity for NASH. A risk score combining the clinical and genetic risk factors resulted in an AUC of 0.80 (95% CI 0.73-0.87).
CONCLUSIONS: A score based on genetic risk factors significantly predicts NASH in obese children with increased liver enzymes, representing a proof-of-principle that genetic scores may be useful to predict long-term outcomes of the disease and guide clinical management.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24345846     DOI: 10.1097/MPG.0000000000000279

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  23 in total

1.  NASPGHAN Clinical Practice Guideline for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease in Children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN).

Authors:  Miriam B Vos; Stephanie H Abrams; Sarah E Barlow; Sonia Caprio; Stephen R Daniels; Rohit Kohli; Marialena Mouzaki; Pushpa Sathya; Jeffrey B Schwimmer; Shikha S Sundaram; Stavra A Xanthakos
Journal:  J Pediatr Gastroenterol Nutr       Date:  2017-02       Impact factor: 2.839

Review 2.  The Krüppel-Like Factors and Control of Energy Homeostasis.

Authors:  Paishiun N Hsieh; Liyan Fan; David R Sweet; Mukesh K Jain
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

3.  EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

Authors: 
Journal:  Diabetologia       Date:  2016-06       Impact factor: 10.122

Review 4.  Non-alcoholic fatty liver disease: what the clinician needs to know.

Authors:  Mariana Verdelho Machado; Helena Cortez-Pinto
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

5.  The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease.

Authors:  Hikmet Akkiz; Emre Taskin; Umit Karaogullarindan; Anil Delik; Sedef Kuran; Ozlem Kutlu
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 6.  Nonalcoholic Fatty liver disease/non-alcoholic steatohepatitis in childhood: endocrine-metabolic "mal-programming".

Authors:  Sara Manti; Claudio Romano; Valeria Chirico; Martina Filippelli; Caterina Cuppari; Italia Loddo; Carmelo Salpietro; Teresa Arrigo
Journal:  Hepat Mon       Date:  2014-05-01       Impact factor: 0.660

7.  Dietary blueberry and bifidobacteria attenuate nonalcoholic fatty liver disease in rats by affecting SIRT1-mediated signaling pathway.

Authors:  Tingting Ren; Chao Huang; Mingliang Cheng
Journal:  Oxid Med Cell Longev       Date:  2014-11-27       Impact factor: 6.543

8.  Effect of a stilbene glycoside-rich extract from Polygoni Multiflori Radix on experimental non-alcoholic fatty liver disease based on principal component and orthogonal partial least squares discriminant analysis.

Authors:  Zhaohuan Lou; Bohou Xia; Jie Su; Jingjing Yu; Meiqiu Yan; Yuefang Huang; Guiyuan Lv
Journal:  Exp Ther Med       Date:  2017-09-22       Impact factor: 2.447

9.  Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study.

Authors:  Umberto Vespasiani-Gentilucci; Chiara Dell'Unto; Antonio De Vincentis; Andrea Baiocchini; Marco Delle Monache; Roberto Cecere; Adriano Maria Pellicelli; Valerio Giannelli; Simone Carotti; Giovanni Galati; Paolo Gallo; Francesco Valentini; Franca Del Nonno; Davide Rosati; Sergio Morini; Raffaele Antonelli-Incalzi; Antonio Picardi
Journal:  Can J Gastroenterol Hepatol       Date:  2018-03-14

Review 10.  A Guide to Non-Alcoholic Fatty Liver Disease in Childhood and Adolescence.

Authors:  Jonathan L Temple; Paul Cordero; Jiawei Li; Vi Nguyen; Jude A Oben
Journal:  Int J Mol Sci       Date:  2016-06-15       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.